Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.42 |
| ▸ | MMP3 | P08254 | 12/20 | 0.42 |
| ▸ | MMP9 | P14780 | 11/20 | 0.42 |
| ▸ | MMP13 | P45452 | 11/20 | 0.42 |
| ▸ | MMP7 | P09237 | 9/20 | 0.42 |
| ▸ | MMP8 | P22894 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053684 | 0.88 | MMP3 (0.43) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7055721 | 0.85 | SMN1; SMN2 (0.34) | MMP1MMP3MMP9MMP13MMP8 | |
| SCHEMBL7056106 | 0.84 | MMP3 (0.53) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7052830 | 0.83 | MMP3 (0.52) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7352469 | 0.82 | MMP3 (0.41) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7057123 | 0.81 | MMP13 (0.46) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7355593 | 0.81 | MMP13 (0.46) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7059354 | 0.81 | MMP3 (0.42) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7056561 | 0.81 | MMP1 (0.46) | MMP1MMP3MMP9MMP13MMP7 | |
| SCHEMBL7056549 | 0.81 | MMP1 (0.49) | MMP1MMP3MMP9MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0948489-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027069-A1 | PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | MMP1 2/4885MMP3 7/4885MMP9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.